CTOs on the Move

G1 Therapeutics

www.g1therapeutics.com

 
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted ...
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.g1therapeutics.com
  • 79 T.W. Alexander Drive 4501 Research Commons Suite 100
    Research Triangle Park, NC USA 27709
  • Phone: 919.213.9835

Executives

Name Title Contact Details
David Elks
Head of Information Technology Profile

Similar Companies

Med-Metrix

Med-Metrix is a leading provider of performance management analytics, consulting, extended business office, and revenue recovery services to the healthcare industry. Our firm was founded by a veteran management team with a successful track record providing superior service and technology to Hospitals.

Michael

Michael is a Franklinton, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world`s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient`s journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Deep Genomics

Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.

JBJS

JBJS is a Needham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.